Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec    EVT   DE0005664809

EVOTEC (EVT)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweetsMarketScreener Strategies

Evotec : There is still some upside potential

share with twitter share with LinkedIn share with facebook
share via e-mail
11/08/2018 | 09:31am CET
long trade
Live
Entry price : 19.67€ | Target : 24€ | Stop-loss : 16€ | Potential : 22.01%
Shares in Evotec do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend.
Investors have an opportunity to buy the stock and target the € 24.
Chart EVOTEC
Duration : Period :
Evotec Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • The company has poor fundamentals for a short-term investment strategy.

Strengths
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The group's high margin levels account for strong profits.
  • The group usually releases upbeat results with huge surprise rates.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 81.62 times its estimated earnings per share for the ongoing year.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Subsector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
EVOTEC44.44%3 279
CELLTRION, INC.--.--%24 315
IQVIA HOLDINGS INC21.69%24 101
LONZA GROUP14.85%22 366
INCYTE CORPORATION-32.27%13 839
SEATTLE GENETICS, INC.-0.79%8 710
EXACT SCIENCES CORPORATION30.28%8 464
QIAGEN10.77%7 966
ICON PLC20.37%7 349
IONIS PHARMACEUTICALS INC-0.48%7 108
ALNYLAM PHARMACEUTICALS, IN..-48.78%7 008
Autres valeurs du secteur

Ulrich Ebensperger
© Zonebourse.com 2018
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (€)
Sales 2018 353 M
EBIT 2018 50,4 M
Net income 2018 49,2 M
Debt 2018 55,0 M
Yield 2018 -
P/E ratio 2018 71,56
P/E ratio 2019 61,42
EV / Sales 2018 8,36x
EV / Sales 2019 7,33x
Capitalization 2 892 M
Upcoming event on EVOTEC
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 22,9 €
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Eugenio Cosimino Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC44.44%3 279
CELLTRION, INC.--.--%24 315
IQVIA HOLDINGS INC21.69%24 101
LONZA GROUP14.85%22 366
INCYTE CORPORATION-32.27%13 839
SEATTLE GENETICS, INC.-0.79%8 710